27594346|t|Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication
27594346|a|Hepatitis delta virus (HDV) in conjunction with hepatitis B virus (HBV) increases adult morbidity and mortality. A number of studies have performed cost-benefit analyses for HBV interventions, but they have ignored the impact of HDV on these outcomes. Using a mathematical model of HBV - HDV epidemiology, we compare health benefits and cost outcomes of four interventions: testing with HBV adult vaccination (diagnosis), diagnosis with antiviral treatment for HBV infections (mono - infections), diagnosis with antiviral treatment for HBV - HDV infections (dual - infections), and awareness programs. The relationship between optimal levels and outcomes of each of these interventions and HDV prevalence in HBV infected individuals ranging from 0 to 50% is determined. Over a 50 year period under no intervention, HBV prevalence, per capita total cost and death toll increase by 2.25%, -$11 and 2.6-fold respectively in moderate HDV endemic regions compared to mono - infected regions; the corresponding values for high HDV endemic regions are 4.2%, -$21 and 3.9-fold. Optimal interventions can be strategized similarly in mono and dually endemic regions. Only implementation of all four interventions achieves a very low HBV prevalence of around 1.5% in a moderate HDV endemic region such as China, with 2.8 million fewer deaths compared to no intervention. Although the policy of implementation of all four interventions costs additional $382 billion compared to no intervention, it still remains cost - effective with an incremental cost - effectiveness ratio of $1400/ QALY. Very high efficacy awareness programs achieve less prevalence with fewer deaths at a lower cost compared to treatment and/or vaccination programs. HDV substantially affects the performance of any HBV - related intervention. Its exclusion results in over-estimation of the effectiveness of HBV interventions.
27594346	16	22	impact	T080	C4049986
27594346	26	51	endemic hepatitis D virus	T005	C0011220
27594346	55	72	hepatitis B virus	T005	C0019169
27594346	73	84	eradication	T058	C3178994
27594346	85	106	Hepatitis delta virus	T005	C0011220
27594346	108	111	HDV	T005	C0011220
27594346	116	127	conjunction	T078	C2699427
27594346	133	150	hepatitis B virus	T005	C0019169
27594346	152	155	HBV	T005	C0019169
27594346	157	166	increases	T169	C0442805
27594346	167	172	adult	T100	C0001675
27594346	173	182	morbidity	T081	C0026538
27594346	187	196	mortality	T081	C0205848
27594346	200	206	number	T081	C0237753
27594346	210	217	studies	T062	C2603343
27594346	223	232	performed	T169	C0884358
27594346	233	254	cost-benefit analyses	T057	C0010174
27594346	259	262	HBV	T005	C0019169
27594346	263	276	interventions	T061	C0184661
27594346	292	299	ignored	T078	C1554079
27594346	304	310	impact	T080	C4049986
27594346	314	317	HDV	T005	C0011220
27594346	327	335	outcomes	T169	C1274040
27594346	345	363	mathematical model	T170	C0876936
27594346	367	370	HBV	T005	C0019169
27594346	373	376	HDV	T005	C0011220
27594346	377	389	epidemiology	T169	C0014508
27594346	394	401	compare	T052	C1707455
27594346	402	417	health benefits	T081	C0086387
27594346	422	426	cost	T081	C0010186
27594346	427	435	outcomes	T169	C1274040
27594346	439	443	four	T081	C0205450
27594346	444	457	interventions	T061	C0184661
27594346	459	466	testing	T169	C0039593
27594346	472	475	HBV	T005	C0019169
27594346	476	481	adult	T100	C0001675
27594346	482	493	vaccination	T061	C0042196
27594346	495	504	diagnosis	T062	C1704656
27594346	507	516	diagnosis	T062	C1704656
27594346	522	541	antiviral treatment	T061	C2363964
27594346	546	560	HBV infections	T047	C0019163
27594346	562	566	mono	T081	C0205171
27594346	569	579	infections	T046	C3714514
27594346	582	591	diagnosis	T062	C1704656
27594346	597	616	antiviral treatment	T061	C2363964
27594346	621	624	HBV	T005	C0019169
27594346	627	630	HDV	T005	C0011220
27594346	631	641	infections	T046	C3714514
27594346	643	647	dual	T080	C1706942
27594346	650	660	infections	T046	C3714514
27594346	677	685	programs	T169	C3484370
27594346	691	703	relationship	T080	C0439849
27594346	712	719	optimal	T080	C2698651
27594346	720	726	levels	T080	C0441889
27594346	731	739	outcomes	T169	C1274040
27594346	757	770	interventions	T061	C0184661
27594346	775	778	HDV	T005	C0011220
27594346	779	789	prevalence	T081	C0220900
27594346	793	796	HBV	T005	C0019169
27594346	797	805	infected	T033	C0439663
27594346	806	817	individuals	T098	C0027361
27594346	855	859	Over	T079	C0347984
27594346	865	869	year	T079	C0439234
27594346	870	876	period	T079	C1948053
27594346	883	898	no intervention	T033	C0243095
27594346	900	903	HBV	T005	C0019169
27594346	904	914	prevalence	T081	C0220900
27594346	916	926	per capita	T081	C0392762
27594346	927	932	total	T080	C0439810
27594346	933	937	cost	T081	C0010186
27594346	942	947	death	T033	C1306577
27594346	948	952	toll	T080	C0439810
27594346	953	961	increase	T169	C0442805
27594346	1006	1014	moderate	T080	C1881878
27594346	1015	1018	HDV	T005	C0011220
27594346	1027	1034	regions	UnknownType	C0681784
27594346	1035	1043	compared	T052	C1707455
27594346	1047	1051	mono	T081	C0205171
27594346	1054	1062	infected	T033	C0439663
27594346	1063	1070	regions	UnknownType	C0681784
27594346	1090	1096	values	T080	C0042295
27594346	1101	1105	high	T080	C0205250
27594346	1106	1109	HDV	T005	C0011220
27594346	1118	1125	regions	UnknownType	C0681784
27594346	1155	1162	Optimal	T080	C2698651
27594346	1163	1176	interventions	T061	C0184661
27594346	1196	1205	similarly	T080	C2348205
27594346	1209	1213	mono	T081	C0205171
27594346	1218	1224	dually	T080	C1706942
27594346	1233	1240	regions	UnknownType	C0681784
27594346	1247	1261	implementation	T052	C1708476
27594346	1269	1273	four	T081	C0205450
27594346	1274	1287	interventions	T061	C0184661
27594346	1288	1296	achieves	T033	C0432600
27594346	1304	1307	low	T080	C0205251
27594346	1308	1311	HBV	T005	C0019169
27594346	1312	1322	prevalence	T081	C0220900
27594346	1352	1355	HDV	T005	C0011220
27594346	1364	1370	region	UnknownType	C0681784
27594346	1379	1384	China	T083	C0008115
27594346	1395	1402	million	T081	C1881839
27594346	1403	1408	fewer	T081	C1611820
27594346	1409	1415	deaths	T081	C0205848
27594346	1416	1424	compared	T052	C1707455
27594346	1428	1443	no intervention	T033	C0243095
27594346	1458	1464	policy	T170	C0242456
27594346	1468	1482	implementation	T052	C1708476
27594346	1490	1494	four	T081	C0205450
27594346	1495	1508	interventions	T061	C0184661
27594346	1509	1514	costs	T081	C0010186
27594346	1515	1525	additional	T169	C1524062
27594346	1531	1538	billion	T081	C0392762
27594346	1539	1547	compared	T052	C1707455
27594346	1551	1566	no intervention	T033	C0243095
27594346	1585	1589	cost	T081	C0010186
27594346	1592	1601	effective	T080	C1704419
27594346	1610	1621	incremental	T081	C1705117
27594346	1622	1626	cost	T081	C0010186
27594346	1629	1642	effectiveness	T080	C1280519
27594346	1643	1648	ratio	T081	C0456603
27594346	1659	1663	QALY	T079	C0080071
27594346	1670	1674	high	T080	C0205250
27594346	1675	1683	efficacy	T080	C1280519
27594346	1694	1702	programs	T169	C3484370
27594346	1711	1715	less	T080	C0205251
27594346	1716	1726	prevalence	T081	C0220900
27594346	1732	1737	fewer	T081	C1611820
27594346	1738	1744	deaths	T081	C0205848
27594346	1750	1755	lower	T080	C0205251
27594346	1756	1760	cost	T081	C0010186
27594346	1761	1769	compared	T052	C1707455
27594346	1773	1782	treatment	T061	C0087111
27594346	1790	1801	vaccination	T061	C0042196
27594346	1802	1810	programs	T169	C3484370
27594346	1812	1815	HDV	T005	C0011220
27594346	1842	1853	performance	T052	C1882330
27594346	1861	1864	HBV	T005	C0019169
27594346	1867	1874	related	T078	C1254370
27594346	1875	1887	intervention	T061	C0184661
27594346	1893	1902	exclusion	T052	C2828389
27594346	1937	1950	effectiveness	T080	C1280519
27594346	1954	1957	HBV	T005	C0019169
27594346	1958	1971	interventions	T061	C0184661